Dariohealth Corp Financials
This page shows Dariohealth Corp (DRIO) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2024 annual data. Scores normalized against common benchmarks. How we calculate these scores
Dariohealth Corp has an operating margin of -213.5%, meaning the company retains $-214 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -276.1% the prior year.
Dariohealth Corp's revenue surged 32.9% year-over-year to $27.0M, reflecting rapid business expansion. This strong growth earns a score of 100/100.
Dariohealth Corp carries a low D/E ratio of 0.33, meaning only $0.33 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 99/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 2.44, Dariohealth Corp holds $2.44 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 77/100.
While Dariohealth Corp generated -$38.6M in operating cash flow, capex of $138K consumed most of it, leaving -$38.7M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
Dariohealth Corp passes 6 of 9 financial strength tests. 2 of 4 profitability signals pass, 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, Dariohealth Corp generates $0.90 in operating cash flow (-$38.6M OCF vs -$42.7M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Dariohealth Corp generated $27.0M in revenue in fiscal year 2024. This represents an increase of 32.9% from the prior year.
Dariohealth Corp's EBITDA was -$50.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 1.7% from the prior year.
Dariohealth Corp generated -$38.7M in free cash flow in fiscal year 2024, representing cash available after capex. This represents a decrease of 25.0% from the prior year.
Dariohealth Corp reported -$42.7M in net income in fiscal year 2024. This represents an increase of 28.1% from the prior year.
Dariohealth Corp earned $0.61 per diluted share (EPS) in fiscal year 2024. This represents a decrease of 68.4% from the prior year.
Dariohealth Corp held $27.8M in cash against $23.5M in long-term debt as of fiscal year 2024.
Dariohealth Corp had 2M shares outstanding in fiscal year 2024. This represents a decrease of 92.9% from the prior year.
Dariohealth Corp's gross margin was 49.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is up 19.7 percentage points from the prior year.
Dariohealth Corp's operating margin was -213.5% in fiscal year 2024, reflecting core business profitability. This is up 62.5 percentage points from the prior year.
Dariohealth Corp's net profit margin was -158.1% in fiscal year 2024, showing the share of revenue converted to profit. This is up 133.9 percentage points from the prior year.
Dariohealth Corp invested $24.2M in research and development in fiscal year 2024. This represents an increase of 19.4% from the prior year.
Dariohealth Corp invested $138K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 76.4% from the prior year.
DRIO Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.0M-6.7% | $5.4M-20.5% | $6.8M+86.7% | $3.6M+2.8% | $3.5M-42.8% | $6.2M-12.9% | $7.1M+3.8% | $6.8M |
| Cost of Revenue | $2.0M-17.2% | $2.4M-16.2% | $2.9M-17.6% | $3.5M+19.8% | $2.9M-28.7% | $4.1M+4.6% | $3.9M-4.4% | $4.1M |
| Gross Profit | $3.0M+1.7% | $3.0M-23.6% | $3.9M+2840.9% | $132K-78.4% | $610K-70.6% | $2.1M-34.5% | $3.2M+16.0% | $2.7M |
| R&D Expenses | $3.3M-10.6% | $3.7M-9.4% | $4.1M-2.1% | $4.2M-25.9% | $5.7M+8.5% | $5.2M+1.1% | $5.2M+8.0% | $4.8M |
| SG&A Expenses | $4.6M+42.2% | $3.2M-3.0% | $3.3M-40.1% | $5.5M+33.9% | $4.1M-6.4% | $4.4M+8.4% | $4.1M+33.9% | $3.0M |
| Operating Income | -$9.5M-3.1% | -$9.2M+2.2% | -$9.4M+33.8% | -$14.2M+8.6% | -$15.5M-10.9% | -$14.0M-13.0% | -$12.4M-37.7% | -$9.0M |
| Interest Expense | $1.2M | N/A | N/A | N/A | N/A | N/A | $1.1M | N/A |
| Income Tax | $0 | N/A | $0 | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$10.5M+19.4% | -$13.0M-40.8% | -$9.2M+35.4% | -$14.3M+9.2% | -$15.7M+5.1% | -$16.6M-29.3% | -$12.8M-1.6% | -$12.6M |
| EPS (Diluted) | $2.96 | $0.18+28.6% | $0.14-65.9% | $0.41-16.3% | $0.49-15.5% | $0.58+28.9% | $0.45+7.1% | $0.42 |
DRIO Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $117.7M+8.7% | $108.3M-6.3% | $115.6M+19.9% | $96.4M-9.5% | $106.5M-9.1% | $117.2M+8.5% | $108.0M-9.4% | $119.2M |
| Current Assets | $42.2M+31.1% | $32.2M-16.6% | $38.6M-18.5% | $47.3M-15.8% | $56.2M-14.5% | $65.8M+18.6% | $55.5M-15.3% | $65.5M |
| Cash & Equivalents | $31.9M+45.3% | $22.0M-21.2% | $27.9M-24.3% | $36.8M-16.1% | $43.9M-16.6% | $52.6M+35.6% | $38.8M-21.4% | $49.4M |
| Inventory | $4.9M+5.6% | $4.6M-0.3% | $4.6M-8.7% | $5.1M-7.5% | $5.5M-7.5% | $5.9M-14.0% | $6.9M-13.6% | $8.0M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | $57.4M0.0% | $57.4M0.0% | $57.4M+37.9% | $41.6M0.0% | $41.6M0.0% | $41.6M0.0% | $41.6M0.0% | $41.6M |
| Total Liabilities | $42.8M-3.5% | $44.3M+5.8% | $41.9M+9.6% | $38.2M-0.6% | $38.5M-0.7% | $38.8M+7.7% | $36.0M-8.2% | $39.2M |
| Current Liabilities | $9.3M-4.9% | $9.8M-49.1% | $19.2M+53.3% | $12.5M+54.1% | $8.1M+0.4% | $8.1M-54.2% | $17.6M-9.0% | $19.4M |
| Long-Term Debt | $30.6M+0.4% | $30.5M+61.4% | $18.9M-23.1% | $24.6M-15.2% | $29.0M-0.3% | $29.1M+73.7% | $16.7M-7.5% | $18.1M |
| Total Equity | $74.9M+17.1% | $64.0M-13.2% | $73.7M+26.8% | $58.1M-14.5% | $68.0M-13.2% | $78.4M+8.8% | $72.0M-10.0% | $80.0M |
| Retained Earnings | -$441.8M-4.5% | -$423.0M-4.6% | -$404.4M-15.8% | -$349.4M-4.6% | -$333.9M-5.3% | -$317.0M-6.1% | -$298.7M-4.5% | -$285.9M |
DRIO Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$7.3M-21.9% | -$6.0M+9.6% | -$6.7M+9.1% | -$7.3M+15.1% | -$8.6M+10.3% | -$9.6M-102.6% | -$4.8M+40.1% | -$7.9M |
| Capital Expenditures | $41K-6.8% | $44K+41.9% | $31K-62.7% | $83K-70.5% | $281K+92.5% | $146K+97.3% | $74K+72.1% | $43K |
| Free Cash Flow | -$7.4M-21.7% | -$6.1M+9.4% | -$6.7M+9.7% | -$7.4M+16.8% | -$8.9M+8.8% | -$9.8M-102.5% | -$4.8M+39.5% | -$8.0M |
| Investing Cash Flow | -$41K+6.8% | -$44K-41.9% | -$31K+62.7% | -$83K+70.5% | -$281K-106.7% | $4.2M+195.8% | -$4.4M-7293.2% | -$59K |
| Financing Cash Flow | $17.4M+13926.6% | $124K-98.2% | $6.8M | $0-100.0% | $204K-99.0% | $19.4M+1499.4% | -$1.4M-624.2% | $265K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
DRIO Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q4'23 | Q3'24 | Q2'24 | Q1'24 | Q4'22 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.2%+5.0pp | 55.2%-2.3pp | 57.5%+53.8pp | 3.6%-13.7pp | 17.3%-16.4pp | 33.7%-11.1pp | 44.8%+4.7pp | 40.1% |
| Operating Margin | -189.4%-18.1pp | -171.3%-32.0pp | -139.3%+253.8pp | -393.1%+48.8pp | -441.9%-214.0pp | -227.9%-52.3pp | -175.6%-43.3pp | -132.3% |
| Net Margin | -209.0%+32.9pp | -241.9%-105.3pp | -136.7%+258.4pp | -395.1%+52.1pp | -447.2%-177.6pp | -269.6%-88.1pp | -181.5%+3.8pp | -185.3% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -8.9%+3.1pp | -12.0%-4.0pp | -8.0%+6.8pp | -14.8%-0.1pp | -14.8%-0.6pp | -14.2%-2.3pp | -11.9%-1.3pp | -10.6% |
| Current Ratio | 4.55+1.2 | 3.30+1.3 | 2.01-1.8 | 3.79-3.1 | 6.93-1.2 | 8.14+5.0 | 3.15-0.2 | 3.39 |
| Debt-to-Equity | 0.41-0.1 | 0.48+0.2 | 0.26-0.2 | 0.420.0 | 0.43+0.1 | 0.37+0.1 | 0.230.0 | 0.23 |
| FCF Margin | -147.6%-34.5pp | -113.1%-13.9pp | -99.3%+106.0pp | -205.3%+48.4pp | -253.7%-94.7pp | -159.0%-90.6pp | -68.4%+48.9pp | -117.3% |
Similar Companies
Frequently Asked Questions
What is Dariohealth Corp's annual revenue?
Dariohealth Corp (DRIO) reported $27.0M in total revenue for fiscal year 2024. This represents a 32.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dariohealth Corp's revenue growing?
Dariohealth Corp (DRIO) revenue grew by 32.9% year-over-year, from $20.4M to $27.0M in fiscal year 2024.
Is Dariohealth Corp profitable?
No, Dariohealth Corp (DRIO) reported a net income of -$42.7M in fiscal year 2024, with a net profit margin of -158.1%.
What is Dariohealth Corp's earnings per share (EPS)?
Dariohealth Corp (DRIO) reported diluted earnings per share of $0.61 for fiscal year 2024. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is Dariohealth Corp's EBITDA?
Dariohealth Corp (DRIO) had EBITDA of -$50.3M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does Dariohealth Corp have?
As of fiscal year 2024, Dariohealth Corp (DRIO) had $27.8M in cash and equivalents against $23.5M in long-term debt.
What is Dariohealth Corp's gross margin?
Dariohealth Corp (DRIO) had a gross margin of 49.1% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Dariohealth Corp's operating margin?
Dariohealth Corp (DRIO) had an operating margin of -213.5% in fiscal year 2024, reflecting the profitability of core business operations before interest and taxes.
What is Dariohealth Corp's net profit margin?
Dariohealth Corp (DRIO) had a net profit margin of -158.1% in fiscal year 2024, representing the share of revenue converted into profit after all expenses.
What is Dariohealth Corp's free cash flow?
Dariohealth Corp (DRIO) generated -$38.7M in free cash flow during fiscal year 2024. This represents a -25.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Dariohealth Corp's operating cash flow?
Dariohealth Corp (DRIO) generated -$38.6M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.
What are Dariohealth Corp's total assets?
Dariohealth Corp (DRIO) had $118.9M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Dariohealth Corp's capital expenditures?
Dariohealth Corp (DRIO) invested $138K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Dariohealth Corp spend on research and development?
Dariohealth Corp (DRIO) invested $24.2M in research and development during fiscal year 2024.
How many shares does Dariohealth Corp have outstanding?
Dariohealth Corp (DRIO) had 2M shares outstanding as of fiscal year 2024.
What is Dariohealth Corp's current ratio?
Dariohealth Corp (DRIO) had a current ratio of 2.44 as of fiscal year 2024, which is generally considered healthy.
What is Dariohealth Corp's debt-to-equity ratio?
Dariohealth Corp (DRIO) had a debt-to-equity ratio of 0.33 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dariohealth Corp's return on assets (ROA)?
Dariohealth Corp (DRIO) had a return on assets of -36.0% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is Dariohealth Corp's cash runway?
Based on fiscal year 2024 data, Dariohealth Corp (DRIO) had $27.8M in cash against an annual operating cash burn of $38.6M. This gives an estimated cash runway of approximately 9 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Dariohealth Corp's Piotroski F-Score?
Dariohealth Corp (DRIO) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dariohealth Corp's earnings high quality?
Dariohealth Corp (DRIO) has an earnings quality ratio of 0.90x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Dariohealth Corp?
Dariohealth Corp (DRIO) scores 55 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.